MARSHALL WACE, LLP

Position in FULC — Fulcrum Therapeutics, Inc.

CIK 1318757 LONDON, X0

Position in FULC

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$4,971,828

+$3,807,792 QoQ

Shares Held

1,358,423

+1219.9% QoQ

Ownership

1.78%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#18

of 154 holders

Holding Since

Sep 2021

12 quarters on record

Voting authority Sole 0% Shared 100% None 0%

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,014,740,742 across 267 Biotechnology names. FULC ranks #105 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	543,897	$270,169,956
2	INCY	Incyte Corp	1,310,154	$148,519,056
3	RPRX	Royalty Pharma plc	2,450,669	$137,409,009
4	SYRE	Spyre Therapeutics, Inc.	991,693	$88,042,503
5	ALNY	Alnylam Pharmaceuticals, Inc.	259,799	$78,207,292
6	TVTX	Travere Therapeutics, Inc.	1,333,207	$75,739,488
7	MANE	Veradermics, Inc	585,560	$71,988,746
8	DFTX	Definium Therapeutics, Inc.	1,298,946	$61,102,419

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$4,971,828	1,358,423	+1219.9%	Shares	Other	2026-08-13
2025-12-31	$1,164,036	102,921	-69.1%	Shares	Other	2026-02-13
2024-06-30	$2,065,597	333,161	+47.7%	Shares	Other	2024-08-14
2024-03-31	$2,129,409	225,573	-55.3%	Shares	Other	2024-05-15
2023-12-31	$3,409,438	505,102	-51.8%	Shares	Other	2024-02-14
2023-09-30	$4,655,988	1,048,646	+5926.7%	Shares	Other	2023-11-14
2023-06-30	$57,420	17,400	-85.6%	Shares	Other	2023-08-14
2023-03-31	$344,850	121,000	+679.3%	Shares	Other	2023-05-15
2022-12-31	$113,029	15,526	-22.8%	Shares	Other	2023-02-14
2022-09-30	$162,730	20,115	+48.9%	Shares	Other	2022-11-14
2021-12-31	$239,044	13,513	-91.1%	Shares	Other	2022-02-14
2021-09-30	$4,279,146	151,689	—	Shares	Sole	2021-11-15
No filing history on record for this holder in this stock.